An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody) or placebo and were followed for type 1 diabetes. Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 7; pp. 603 - 613
Main Authors Herold, Kevan C, Bundy, Brian N, Long, S. Alice, Bluestone, Jeffrey A, DiMeglio, Linda A, Dufort, Matthew J, Gitelman, Stephen E, Gottlieb, Peter A, Krischer, Jeffrey P, Linsley, Peter S, Marks, Jennifer B, Moore, Wayne, Moran, Antoinette, Rodriguez, Henry, Russell, William E, Schatz, Desmond, Skyler, Jay S, Tsalikian, Eva, Wherrett, Diane K, Ziegler, Anette-Gabriele, Greenbaum, Carla J
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 15.08.2019
Subjects
Adolescent
Adult
Age
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Autoimmune diseases
Beta cells
CD3 antigen
CD3 Complex - antagonists & inhibitors
CD8 antigen
Child
Clinical trials
Diabetes
Diabetes mellitus
Diabetes mellitus (insulin dependent)
Diabetes Mellitus, Type 1 - genetics
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 1 - prevention & control
Diagnosis
Disease Progression
Double-Blind Method
Drug dosages
Exanthema - chemically induced
Fc receptors
Female
Glucose
Glucose tolerance
Glucose Tolerance Test
Histocompatibility antigen HLA
HLA-DR3 Antigen
HLA-DR4 Antigen
Humans
Hyperglycemia
Immunological tolerance
Insulin
KLRG1 protein
Laboratories
Lymphocyte Count
Lymphocytes T
Lymphopenia
Lymphopenia - chemically induced
Male
Medical diagnosis
Metabolism
Middle Aged
Monoclonal antibodies
Proportional Hazards Models
T-Lymphocytes - immunology
Tissue engineering
Young Adult
Zinc transporter
Online AccessGet full text

Cover

More Information
Summary:In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody) or placebo and were followed for type 1 diabetes. Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1902226